What are the marketed Direct oral anticoagulant (DOAC) — direct thrombin inhibitor drugs?

Marketed Direct oral anticoagulant (DOAC) — direct thrombin inhibitor drugs include Pradaxa, Rivaroxaban, Dabigatran, No OAC, Rivaroxaban, dabigatran, apixaban, or edoxaban, Dabigatran; Rivaroxaban.

Direct oral anticoagulant (DOAC) — direct thrombin inhibitor

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5 marketed 5 in Phase 3 1 in Phase 2

This page covers all Direct oral anticoagulant (DOAC) — direct thrombin inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone], Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran), Factor Xa.

Targets

Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] · Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran) · Factor Xa · Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran) · Dabigatran: Factor IIa (thrombin); Rivaroxaban: Factor Xa · Factor Xa or Factor IIa (thrombin) · Dabigatran: Factor IIa (thrombin); Apixaban: Factor Xa · Factor Xa or thrombin · Factor Xa (coagulation Factor X, activated form)

Marketed (5)

Pradaxa · Generic (originally Boehringer Ingelheim) · Cardiovascular · 1200
Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring.
Rivaroxaban, Dabigatran · University Hospital, Grenoble · Cardiovascular
These are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation.
No OAC · Pfizer · Cardiovascular
Rivaroxaban, dabigatran, apixaban, or edoxaban · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · Cardiovascular
These are direct oral anticoagulants (DOACs) that inhibit specific clotting factors to prevent blood clot formation.
Dabigatran; Rivaroxaban · University Hospital, Grenoble · Cardiovascular
Both dabigatran and rivaroxaban are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation.

Phase 3 pipeline (5)

Continuous DOAC therapy · Johns Hopkins University · Cardiovascular
Continuous DOAC therapy maintains uninterrupted anticoagulation using direct oral anticoagulants without treatment gaps.
Dabigatran and Apixaban · University of Sao Paulo General Hospital · Cardiovascular
Dabigatran and apixaban are direct oral anticoagulants that inhibit blood clotting factors to prevent thromboembolism.
Full dose of DOAC · University Hospital, Brest · Cardiovascular
Direct oral anticoagulants (DOACs) inhibit specific clotting factors to prevent blood clot formation.
Reduced dose of DOAC · University Hospital, Brest · Cardiovascular
A reduced dose of a direct oral anticoagulant (DOAC) inhibits specific coagulation factors to prevent thrombus formation while minimizing bleeding risk through dose optimization.
Direct oral anticoagulant · Centre Hospitalier Universitaire de Nīmes · Cardiovascular
Direct oral anticoagulants inhibit specific clotting factors to prevent blood clot formation.

Phase 2 pipeline (1)

DOACs: Rivaroxaban, Dabigatran, Apixaban · Bayer · Cardiovascular
Rivaroxaban, dabigatran, and apixaban are direct oral anticoagulants that inhibit Factor Xa or thrombin.

Patent intelligence

direct oral anticoagulant patent landscape — aggregated cliff calendar, attackable patents, originator estates